Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:03 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 33,137 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults

NCT01050127
View directory record Official record
Conditions
Healthy
Interventions
ABT-436, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

NCT04785794
View directory record Official record
Conditions
Influenza Vaccine
Interventions
Sing2016 M2SR H3N2 influenza vaccine, Placebo
Biological · Other
Lead sponsor
FluGen Inc
Industry
Eligibility
50 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional

Role of Slowly Digesible Starch on Diabetes Risk Factors

NCT01708694
View directory record Official record
Conditions
Prediabetes
Interventions
Amylose, Amylopectin
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
35 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

NCT00000866
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1, TBC-3B Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 4 Interventional Results available

Zonisamide vs. Placebo in the Treatment of Alcohol Dependence

NCT00595556
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse, Alcohol Dependence
Interventions
zonisamide, Placebo
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Nov 3, 2026, 6:03 PM EST
Recruiting Not applicable Interventional

Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes

NCT06735651
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Cognition, Oxidative Stress, Gut Microbiota, Overweight, Inflammation, Microvascular Function, Body Composition
Interventions
Wild Blueberry, Placebo
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
20 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

Dexamethasone or Clonidine as Adjuncts to Ropivacaine for Caudal Analgesia on Analgesia Duration in Children

NCT02773602
View directory record Official record
Conditions
Postoperative Pain
Interventions
Dexamethasone, Clonidine, Normal Saline
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Months to 6 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Nov 3, 2026, 6:03 PM EST
Recruiting Phase 2 Interventional

Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)

NCT05042102
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Donepezil + Cognitive remediation therapy (CRT), Donepezil + Placebo CRT, Placebo medication + Cognitive remediation therapy (CRT), Placebo medication + Placebo CRT
Combination Product
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 2 Interventional

A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection

NCT00038272
View directory record Official record
Conditions
HIV Infections
Interventions
Mycophenolate mofetil, Amdoxovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 3, 2026, 6:03 PM EST
Terminated Phase 2 Interventional

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

NCT04377945
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease
Interventions
Part 1, JM-010 component Group A, Part 1, JM-010 component Group B, Part 1, JM-010 component Group C, Part 1, Placebo Group, Part 2, JM-010 combination Group A, Part 2, JM-010 combination Group B, Part 2, JM-010 component Group C, Part 2, Placebo Group
Drug
Lead sponsor
Bukwang Pharmaceutical
Industry
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Miami, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 Vaccine, Placebo
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
50 Years to 64 Years
Enrollment
5,240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
196
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons

NCT01218113
View directory record Official record
Conditions
AIDS
Interventions
GSK Biologicals HIV Vaccine 732462, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Bakersfield, California • Long Beach, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Reduction During Intrauterine Device (IUD) Insertion in Outpatient Gynecology

NCT06335823
View directory record Official record
Conditions
IUD Insertion Pain
Interventions
Transcutaneous electrical nerve stimulation (TENS), Placebo Transcutaneous electrical nerve stimulation (TENS)
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

NCT04410523
View directory record Official record
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 4 Interventional Results available

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

NCT01981759
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Delusional Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 68 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 2 Interventional Results available

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

NCT02309359
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ALX-0061, Placebo, Methotrexate
Biological · Other · Drug
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years to 74 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Hemet, California • La Palma, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Nov 3, 2026, 6:03 PM EST
Recruiting Phase 3 Interventional

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

NCT07743580
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Secutrelvir, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
12 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Coral Gables, Florida • Hialeah, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 2 Interventional Results available

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

NCT04603027
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
EDP1815, Placebo
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Santa Rosa, California • Orlando, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional Results available

Oxytocin in Cocaine Dependence

NCT01573273
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Oxytocin, Saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 3 Interventional Results available

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300469
View directory record Official record
Conditions
Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
Interventions
ABT-335, Atorvastatin, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

NCT06555783
View directory record Official record
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 6:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

NCT06547554
View directory record Official record
Conditions
Bacterial Infections
Interventions
Xeruborbactam, Cefiderocol, Xeruborbactam/Cefiderocol, Dextrose 5% in water
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Role of Serotonin in Acute and Subacute MDMA Effects

NCT00838305
View directory record Official record
Conditions
MDMA Mechanism of Action
Interventions
MDMA and citalopram, Placebo
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Nov 3, 2026, 6:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

NCT00938405
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hyperlipidemias
Interventions
Colesevelam HCl, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Nov 3, 2026, 6:03 PM EST